Molecularly Targeted Therapies for Dysimmune Neuropathies

From an article in Molecular Medicine by Andreas A Argyriou
(Mol Med. 2009 Jul–Aug; 15(7-8): 283–287. Published online 2009 May 5. doi: 10.2119/molmed.2009.00041.)

“Conventional treatment options, including corticosteroids, intravenous immunoglobulin, or plasma exchange,

[B][COLOR=”Red”]often fail to treat[/COLOR][/B] (Color and Italics are mine)

dysimmune neuropathies, such as

chronic inflammatory demyelinating polyneuropathy,
multifocal motor neuropathy, and
monoclonal gammopathy with its subtypes.

…the need for the development of safe and effective new treatment options is rising. Currently, …”

Wanna know more? To navigate to the link, highlight the green text, copy (ctrl + C) the green link and paste (Crtl + V) it into your browser’s address bar.

[COLOR=”SeaGreen”]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707512/[/COLOR]

Thanks to ms. judy for her question!